KR102892239B1 - Akt 억제제 - Google Patents

Akt 억제제

Info

Publication number
KR102892239B1
KR102892239B1 KR1020217027161A KR20217027161A KR102892239B1 KR 102892239 B1 KR102892239 B1 KR 102892239B1 KR 1020217027161 A KR1020217027161 A KR 1020217027161A KR 20217027161 A KR20217027161 A KR 20217027161A KR 102892239 B1 KR102892239 B1 KR 102892239B1
Authority
KR
South Korea
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
paragraph
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217027161A
Other languages
English (en)
Korean (ko)
Other versions
KR20210120054A (ko
Inventor
창유 마
허 티안
지에 안
지안리앙 자오
동휘 천
지안 우
단 수
춘시아 주
조우샨 티안
Original Assignee
난징 치아 타이 티안큉 파마슈티컬 컴파니 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 난징 치아 타이 티안큉 파마슈티컬 컴파니 리미티드 filed Critical 난징 치아 타이 티안큉 파마슈티컬 컴파니 리미티드
Publication of KR20210120054A publication Critical patent/KR20210120054A/ko
Application granted granted Critical
Publication of KR102892239B1 publication Critical patent/KR102892239B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
KR1020217027161A 2019-01-29 2020-01-22 Akt 억제제 Active KR102892239B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201910084801.3 2019-01-29
CN201910084801 2019-01-29
PCT/CN2020/073798 WO2020156437A1 (zh) 2019-01-29 2020-01-22 Akt抑制剂

Publications (2)

Publication Number Publication Date
KR20210120054A KR20210120054A (ko) 2021-10-06
KR102892239B1 true KR102892239B1 (ko) 2025-11-26

Family

ID=71841634

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217027161A Active KR102892239B1 (ko) 2019-01-29 2020-01-22 Akt 억제제

Country Status (10)

Country Link
US (1) US20220144821A1 (https=)
EP (1) EP3919491B1 (https=)
JP (2) JP7617005B2 (https=)
KR (1) KR102892239B1 (https=)
CN (2) CN117964620A (https=)
AU (1) AU2020214258B2 (https=)
CA (1) CA3127884A1 (https=)
ES (1) ES3037595T3 (https=)
PL (1) PL3919491T3 (https=)
WO (1) WO2020156437A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI908780B (zh) * 2020-03-17 2025-12-21 大陸商江蘇恆瑞醫藥股份有限公司 稠合二環類衍生物、其製備方法及其在醫藥上的應用
CN115485276B (zh) * 2020-05-15 2024-05-31 南京正大天晴制药有限公司 氘代akt激酶抑制剂
CN119302960A (zh) * 2020-07-22 2025-01-14 南京正大天晴制药有限公司 Akt抑制剂的单位剂量组合物
WO2022017448A1 (zh) * 2020-07-22 2022-01-27 南京正大天晴制药有限公司 一种二氢吡啶并[2,3-d]嘧啶酮衍生物的盐及晶型
CN115836069B (zh) * 2020-07-22 2024-02-06 南京正大天晴制药有限公司 一种二氢吡啶并[2,3-d]嘧啶酮衍生物的盐、其制备方法及用途
CN116478156A (zh) * 2022-01-17 2023-07-25 南京正大天晴制药有限公司 一种akt抑制剂化合物的富马酸盐晶型及其制备方法
WO2024146599A1 (zh) * 2023-01-06 2024-07-11 南京正大天晴制药有限公司 一种二氢吡啶并[2,3-d]嘧啶酮的衍生物、其制备方法以及医药用途
CN121586576A (zh) 2023-06-14 2026-02-27 南京正大天晴制药有限公司 Akt抑制剂在制备预防或治疗乳腺癌药物中的用途
CN120157686A (zh) * 2023-12-14 2025-06-17 南京正大天晴制药有限公司 一种具有降解akt激酶活性的化合物及其制备方法和药学上的应用
CN121177294B (zh) * 2025-11-27 2026-02-27 四川省医学科学院·四川省人民医院 Akt抑制剂在制备诱导胰岛移植免疫耐受药物中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2546754A1 (en) * 2003-11-21 2005-06-09 Array Biopharma Inc. Akt protein kinase inhibitors
US20130065908A1 (en) * 2009-12-07 2013-03-14 Array Biopharma Inc. Dihydrofuro pyrimidines as akt protein kinase inhibitors
UA95641C2 (xx) 2006-07-06 2011-08-25 Эррей Биофарма Инк. Гідроксильовані піримідильні циклопентани як інгібітори акт протеїнкінази$гидроксилированные пиримидильные циклопентаны как ингибиторы акт протеинкиназы
US8329701B2 (en) 2006-07-06 2012-12-11 Array Biopharma Inc. Dihydrofuro pyrimidines as AKT protein kinase inhibitors
EP2049500B1 (en) 2006-07-06 2011-09-07 Array Biopharma, Inc. Cyclopenta [d] pyrimidines as akt protein kinase inhibitors
CA2711782C (en) 2008-01-09 2017-01-03 Array Biopharma Inc. 5h-cyclopenta[d]pyrimidines as akt protein kinase inhibitors
MX2012004780A (es) * 2009-10-23 2012-08-23 Lilly Co Eli Inhibidores de akt.
CA2890288A1 (en) * 2012-11-16 2014-05-22 Merck Patent Gmbh Novel heterocyclic derivatives as modulators of kinase activity
AR093511A1 (es) * 2012-11-16 2015-06-10 Merck Patent Gmbh Derivados de imidazol-piperidinilo como moduladores de la actividad de cinasas
EP3189036B1 (en) * 2014-09-05 2023-07-19 ArQule, Inc. Compositions and methods for treating proliferation disorders
CN109020957B (zh) * 2017-06-12 2023-01-13 南京天印健华医药科技有限公司 作为mnk抑制剂的杂环化合物
CN108503645A (zh) * 2018-03-01 2018-09-07 山东大学 含氨甲基的哌嗪酮类化合物及其制备方法和应用
ES2969982T3 (es) * 2018-04-24 2024-05-23 Vertex Pharma Compuestos de pteridinona y usos de los mismos

Also Published As

Publication number Publication date
US20220144821A1 (en) 2022-05-12
CN113272304B (zh) 2024-03-29
EP3919491A1 (en) 2021-12-08
JP7617005B2 (ja) 2025-01-17
EP3919491A4 (en) 2022-10-19
WO2020156437A1 (zh) 2020-08-06
PL3919491T3 (pl) 2025-10-20
EP3919491C0 (en) 2025-05-28
CN117964620A (zh) 2024-05-03
KR20210120054A (ko) 2021-10-06
EP3919491B1 (en) 2025-05-28
CN113272304A (zh) 2021-08-17
AU2020214258A1 (en) 2021-09-16
CA3127884A1 (en) 2020-08-06
ES3037595T3 (en) 2025-10-03
JP2024175091A (ja) 2024-12-17
AU2020214258B2 (en) 2025-08-28
JP2022517866A (ja) 2022-03-10

Similar Documents

Publication Publication Date Title
KR102892239B1 (ko) Akt 억제제
CN112778276B (zh) 作为shp2抑制剂的化合物及其应用
EP4417607A1 (en) Heterocyclic compound as sos1 inhibitor and uses thereof
KR20230170658A (ko) 유비퀴틴 특이적 프로테아제 1(usp1) 억제제
CA3105721A1 (en) Fused pyrazine derivatives as a2a / a2b inhibitors
JP5993010B2 (ja) ピリミド−ピリダジノン化合物及びその使用
WO2015101293A1 (zh) 激酶抑制剂及其用途
CN115504980B (zh) 嘧啶并含氮六元芳香杂环类化合物及其用途
TW201912645A (zh) 吡咯並三嗪類衍生物、其製備方法及其用途
CN104910137A (zh) Cdk激酶抑制剂
US20230113478A1 (en) Quinazoline Compounds, Preparation Method, Use, and Pharmaceutical Composition Thereof
JP2016526545A (ja) スルホキシイミン置換キナゾリンならびにｍｎｋ１および／またはｍｎｋ２キナーゼ阻害薬としてのその使用
CN115916350B (zh) Akt抑制剂的单位剂量组合物
CA3114147A1 (en) Fgfr4 inhibitor and use thereof
EP4269402A1 (en) Aromatic heterocyclic compound, pharmaceutical composition and use thereof
CN115485276B (zh) 氘代akt激酶抑制剂
CN115536660A (zh) 苄氨基取代的杂多环化合物及其组合物、制剂和用途
JP2016539148A (ja) 医薬組成物のためのスルホキシイミン置換キナゾリン
EP4310081A1 (en) Ctla-4 small molecule degradation agent and application thereof
CN116249692A (zh) 吡唑类化合物及其制备方法和用途
CN113620976A (zh) 噻唑并嘧啶类化合物及其制备方法、用途和药物组合物
HK40050826A (en) Akt inhibitor
HK40050826B (zh) Akt抑制剂
HK40070481A (en) Fgfr inhibitors and methods of use thereof
HK1223089B (en) Kinase inhibitor and use thereof

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)